Reading the tape
NASDAQ: CAI
Caris Life Sciences, Inc.
Healthcare · Biotechnology
Data caution
Per-share valuation inputs need verification
Event dated Dec 31, 2025Market-derived shares outstanding and recent statement shares differ materially. Per-share ratios and valuation outputs may be unreliable until the share base is verified. This sometimes appears with ADRs or provider share-count gaps.
Market Cap
$5.28B
52w High
$42.50
52w Low
$16.28
P/E
-458.97
Volume
1.32M
Outstanding Shares
282.58M
Price vs Fundamentals
Why The Stock Is Moving
Likely multiple compressionModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -33.25%Revenue (TTM): 121.11%FCF (TTM): 105.41%
What changed
The stock fell 33.25% over the last year. Revenue grew 121.11% over the trailing twelve months. Operating margin moved from 25.07% to 5.56%. Free cash flow grew 105.41% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently 5.56%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CEODavid Dean Halbert
SectorHealthcare
IndustryBiotechnology
Employees1,769
IPO dateJun 18, 2025
Valuation
Forward P/E—
EV/EBITDA3,927.35
Enterprise value$44.69B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth192.74%
Gross margin66.4%▲53.11%vs FY2024
Operating margin5.56%▲108.91%vs FY2024
ROE-93.18%▼926.04%vs FY2024
Analyst consensus
RatingBuy
Target price$28.75▲53.83%
5
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.03 · Revenue est $209.32M
View